Back to results
US 12,668,622 B2Granted
Calreticulin nanobodies
AssigneeActinium Pharmaceuticals, Inc.
InventorsGholamreza Hassanzadeh Ghassabeh, Steve Schoonooghe, Helen Kotanides
Life of this patent
Estimating the term…
Abstract
Provided are nanobodies that bind human calreticulin, fusion proteins including the nanobodies, pharmaceutical compositions including the nanobodies or fusion proteins, and radioconjugates of the nanobodies or fusion proteins.
Claims21
A protein comprising a human-calreticulin binding nanobody amino acid sequence comprising the CDR1, CDR2, and CDR3 sequences:
- (i) SEQ ID NO:18, SEQ ID NO:
- 41, and SEQ ID NO:60, respectively;
- (ii) SEQ ID NO:21, SEQ ID NO:
- 44, and SEQ ID NO:63, respectively;
- (iii) SEQ ID NO:26, SEQ ID NO:49, and SEQ ID NO:68, respectively;
- (iv) SEQ ID NO:22, SEQ ID NO:45, and SEQ ID NO:64, respectively;
- (v) SEQ ID NO:14, SEQ ID NO:39, and SEQ ID NO:58, respectively;
- (vi) SEQ ID NO:20, SEQ ID NO:43, and SEQ ID NO:62, respectively;
- or
- (vii) SEQ ID NO:19, SEQ ID NO:
- 42, and SEQ ID NO:61, respectively.
8 more elements
A protein comprising one or more of the human-calreticulin binding nanobody amino acid sequences set forth in SEQ ID NOS:
- 120, 126, 131, 127, 115, 111, 125 or 123.
Dependencies are inferred from the claim text.